Jenoptik Sees First-Quarter Orders Soar 74%, Lifts Earnings Margin

Jenoptik AG shook things up with a hefty 74% jump in its first-quarter order intake compared to the same stretch last year, hitting €357 million versus €205 million. This boost is largely on the back of a significant order in its Semiconductor & Advanced Manufacturing unit, which has been a clear growth engine.

The company's Biophotonics division also chipped in, seeing an uptick across medical tech, life sciences, and defense sectors. Yet, even with orders climbing, first-quarter sales slightly dipped by 1% to €241 million, a sign that booking momentum hasn't fully translated into revenue yet.

On the brighter side, Jenoptik managed to ramp up its EBITDA to €44.4 million, a solid 22.5% increase over last year's Q1. This pushed the EBITDA margin from 14.9% a year ago to 18.4%, reflecting a cleaner product mix, absence of relocation expenses from its Dresden plant, and ongoing cost-cutting efforts.

Digging deeper, the book-to-bill ratio vaulted to 1.48 from 0.84, highlighting that orders outpaced shipments quite markedly. Their backlog also fattened, climbing to €719.2 million from €591 million by the end of 2025 - a substantial buildup hinting at a busier pipeline ahead.

But it's not all roses. The free cash flow before interest and taxes shrank to €15.9 million from €28.9 million year-over-year. This drop is tied to more working capital tied up as demand ramps up, dampening liquidity in the short term.

Jenoptik stuck to its 2026 game plan, calling for single-digit revenue growth over 2025's €1,046 million haul, along with a target EBITDA margin nestled between 19% and 21%. Capital expenditure is expected to come in just under last year's €77.4 million.

The CFO struck a note of caution on the order intake pace, saying the current brisk clip isn't expected to last all year but still lays down a solid groundwork going forward. This hints at some tempering of expectations as the year progresses.

In all, Jenoptik's Q1 saw a flurry of orders leading to margin expansion despite stagnant sales and a squeeze on cash flow. Whether that momentum sustains or tapers will likely shape the company's trajectory in the months ahead.